Migraine Nasal Spray Market Analysis

Treatment Segment Analysis

Based on treatment, the acute treatment segment is projected to garner the largest revenue share of 72.3% in the migraine nasal spray market during the forecast period. The dominance of this segment is the immediate and high unmet need to diminish migraine attacks after they start restoring patient function. Also, the fast-acting nature of nasal sprays is highly essential for acute care, which is constantly fostering a favorable business environment for the migraine nasal spray industry.

Distribution Channel Segment Analysis

In terms of the distribution channel, the retail pharmacies segment is projected to attain a lucrative share of 55.7% in the market by the end of 2035.  In July 2022, GH Supply Chain noted that Retail pharmacies are playing an increasingly vital role in medicine access across low- and middle-income countries, often filling critical gaps left by under-resourced public healthcare systems. As highlighted by the MTaPS program, incorporating retail pharmacies into national supply chains can enhance access to essential medicines, particularly where government distribution falls short.

Drug Class Segment Analysis

Based on drug class, the CGRP antagonist segment is anticipated to capture a significant share of 48.5% in the migraine nasal spray market during the discussed timeframe. The growth in the segment originates from its superior efficacy and targeted mechanism when compared to fewer cardiovascular contractions when compared to triptans. In August 2025, Teva Pharmaceuticals Industries reported that the U.S. FDA approved an expanded indication for its AJOVY (fremanezumab-vfrm), making it the first anti-CGRP treatment approved for preventive use in children and adolescents with episodic migraine.

Our in-depth analysis of the market includes the following segments: